AlphaQuest LLC Boosts Stock Position in Dynavax Technologies Corporation $DVAX

AlphaQuest LLC grew its holdings in Dynavax Technologies Corporation (NASDAQ:DVAX) by 109.9% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 173,140 shares of the biopharmaceutical company’s stock after purchasing an additional 90,641 shares during the period. AlphaQuest LLC owned about 0.15% of Dynavax Technologies worth $1,719,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in DVAX. Osaic Holdings Inc. increased its stake in Dynavax Technologies by 15.1% in the 2nd quarter. Osaic Holdings Inc. now owns 9,336 shares of the biopharmaceutical company’s stock worth $93,000 after buying an additional 1,226 shares during the period. Callan Family Office LLC purchased a new stake in Dynavax Technologies in the 2nd quarter valued at about $107,000. Summit Global Investments purchased a new position in shares of Dynavax Technologies during the third quarter worth approximately $113,000. Catalyst Funds Management Pty Ltd bought a new stake in shares of Dynavax Technologies during the second quarter valued at approximately $121,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Dynavax Technologies in the third quarter valued at approximately $122,000. 96.96% of the stock is currently owned by institutional investors.

Dynavax Technologies Stock Performance

Shares of Dynavax Technologies stock opened at $15.48 on Friday. The company has a market capitalization of $1.82 billion, a PE ratio of -41.84 and a beta of 0.89. The company has a 50-day simple moving average of $13.53 and a two-hundred day simple moving average of $11.50. Dynavax Technologies Corporation has a one year low of $9.20 and a one year high of $15.73. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.94 and a current ratio of 7.62.

Dynavax Technologies (NASDAQ:DVAX) last released its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported $0.21 earnings per share for the quarter, beating analysts’ consensus estimates of $0.14 by $0.07. The business had revenue of $94.88 million for the quarter, compared to analysts’ expectations of $94.00 million. Dynavax Technologies had a negative net margin of 13.13% and a positive return on equity of 7.18%. Research analysts expect that Dynavax Technologies Corporation will post 0.32 EPS for the current fiscal year.

Insider Transactions at Dynavax Technologies

In other news, COO David F. Novack sold 114,000 shares of the company’s stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $15.64, for a total transaction of $1,782,960.00. Following the transaction, the chief operating officer directly owned 63,344 shares of the company’s stock, valued at approximately $990,700.16. This represents a 64.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 2.98% of the company’s stock.

Analyst Upgrades and Downgrades

DVAX has been the topic of several research reports. William Blair downgraded Dynavax Technologies from an “outperform” rating to a “hold” rating in a report on Wednesday, December 24th. Weiss Ratings reissued a “sell (d)” rating on shares of Dynavax Technologies in a research report on Wednesday, January 21st. Finally, Wall Street Zen upgraded Dynavax Technologies from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 27th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $24.33.

Dynavax Technologies Profile

Dynavax Technologies Corporation is a biopharmaceutical company focused on the development and commercialization of novel vaccines and immunotherapies. Headquartered in Emeryville, California, the company specializes in leveraging its proprietary Toll-like receptor (TLR) agonist platform to enhance immune responses. Its lead product, HEPLISAV-B, is a two-dose hepatitis B vaccine approved by the U.S. Food and Drug Administration that incorporates the CpG 1018 adjuvant to stimulate a rapid and robust antibody response in adults.

Founded in 1993, Dynavax has built a pipeline that extends beyond hepatitis B to include candidates targeting seasonal influenza, respiratory syncytial virus (RSV) and emerging infectious diseases.